|
|
|
| Observation on Effect of Butylphthalide Soft Capsule on Early Senile Parkinson's Disease |
| JIANG Ying, LIANG Jianfen, ZHANG Xingbo, et al |
| The First Affiliated Hospital of Guangxi University of Chinese Medicine, Guangxi Nanning 530023, China |
|
|
|
|
Abstract Objective: To investigate the clinical efficacy of butylphthalide soft capsule in the treatment of early senile Parkinson's disease (PD) and analyze its possible mechanism through the change of serological indexes. Methods: 82 PD patients from January 2017 to December 2018 were selected and divided into control group and observation group according to the random number table, 41 cases each. Two groups of patients were given dopaminergic drugs, the observation group on this basis combined with soft capsules of butylphthalide oral, the treatment cycle was 12 weeks. Before and after treatment, Hoehn & Yahr classification (H-Y classification) and mds-updrs (Part 1 and Part 3) were used to evaluate the clinical efficacy. Meanwhile, the activities of superoxide dismutase (SOD), malondialdehyde (MDA), interleukin-6 (IL-6) and neuron specific enolase (NSE) were measured. Results: The MDS-UPDRS-1, MDS-UPDRS-3, and HY scores of Parkinson's disease patients in the observation group after treatment were lower than those in the control group. After treatment in the control group, their SOD, MDA, Both IL-6 and NSE improved in different degrees. After treatment, their SOD activity in the observation group increased significantly compared with that before treatment, and their MDA, IL-6, and NSE significantly decreased compared with before treatment. The difference was statistically significant (P<0.05). Conclusion: The Butylphthalide soft capsules combined with Dopaminergic drugs can reduce the H-Y grade, MDS-UPDRS-1, MDS-UPDRS-3 scores of early PD patients, improve their SOD, MDA, IL-6, NSE levels, and improve the prognosis of patients with PD.
|
|
|
|
|
|
[1] GBD,2016 Parkinson's Disease Collaborators.Global, regional, and national burden of parkinson's disease, 1990-2016: a systematic analysis for the global burden of disease study 2016[J].Lancet Neurol,2018,17(11) :939~953.
[2] 中华医学会神经病学分会帕金森病及运动障碍学组,中国医师协会神经内科医师分会帕金森病及运动障碍专业委员会.中国帕金森病的诊断标准(2016版)[J].中华神经科杂志,2016,49(4):268~271.
[3] Simon DK,Tanner CM,Brundin P. Parkinson disease epidemiology, pathology, genetics, and pathophysiology[J]. Clin Geriatr Med,2020,36(1):1~12.
[4] Nasrolahi A,Mahmoudi J,Akbarzadeh A,et al. Neurotrophic factors hold promise for the future of parkinson's disease treatment: is there a light at the end of the tunnel[J]. Reviews in the Neurosciences,2018,29(5):475~489.
[5] 崔冰冰,尹榕,刘天珍,等.丁苯酞的药理作用及临床疗效研究进展[J].解放军医药杂志,2019,31(6):11~14.
[6] Chen XQ, Qiu K, Liu H,et al.Application and prospects of butylphthalide for the treatment of neurologic diseases[J].Chinese Medical Journal,2019,132(12):1467~1477.
[7] Chen Y,Wu T,Li H,et al. Dl-3-n-butylphthalide exerts dopaminergic neuroprotection through inhibition of neuroinflammation[J].Front Aging Neurosci,2019,11 :44.
[8] Zhou H, Ye M, Xu W,et al.DL-3-n-butylphthalide therapy for parkinson's disease: a randomized controlled trial[J].Exp Ther Med,2019,17(5):3800~3806.
[9] Haque A,Ray SK,Cox A,et al.Neuron specific enolase:a promising therapeutic target in acute spinal cord injury[J].Metab Brain Dis,2016,31(3):487~495. |
|
|
|
2020, Vol. 26 
